These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34389184)

  • 1. Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO).
    Goicoechea M; Álvarez V; Segarra A; Polaina M; Martín-Reyes G; Robles NR; Escudero V; Orellana C; Bea Granell S; de Juan-Ribera J; Fernández Lucas M; Graña JM; Reque J; Sánchez Hernández R; Villamayor S; Górriz JL
    Nefrologia (Engl Ed); 2021 Aug; ():. PubMed ID: 34389184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO).
    Goicoechea M; Álvarez V; Segarra A; Polaina M; Martín-Reyes G; Robles NR; Escudero V; Orellana C; Bea Granell S; de Juan-Ribera J; Fernández Lucas M; Graña JM; Reque J; Sánchez Hernández R; Villamayor S; Górriz JL
    Nefrologia (Engl Ed); 2022; 42(3):301-310. PubMed ID: 36210619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU).
    Masana L; López Miranda J; Civeira F; Reinares L; Guijarro C; Plana N; Cuenca R; Sánchez D; Hernández JL; Andrés R; Blanco A; Villamayor S
    Clin Investig Arterioscler; 2020; 32(5):183-192. PubMed ID: 32317124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study.
    Blanco Echevarría A; García Díaz JD; Caixas A; Plana Gil N; Rico Corral MÁ; Bridges I; Dhalwani N; Gatell Menchen S; Ray KK
    Clin Investig Arterioscler; 2023; 35(6):263-271. PubMed ID: 37236829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study.
    Barrios V; Escobar C; Arrarte V; García E; Fernández MR; Rincón LM; Roldán C
    Clin Investig Arterioscler; 2020; 32(6):231-241. PubMed ID: 32605806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population.
    Iqbal S; Sabbour HM; Siddiqui MS; Tikriti AA; Santos RD; Buckley A
    Clin Ther; 2022 Oct; 44(10):1297-1309. PubMed ID: 36127165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
    Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
    Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
    Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab.
    McDonagh M; Peterson K; Holzhammer B; Fazio S
    J Manag Care Spec Pharm; 2016 Jun; 22(6):641-653q. PubMed ID: 27231792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study.
    Sudano I; Krähenbühl S; Mach F; Anstett A; Dhalwani N; Bridges I; Sibartie M; Ray KK
    Ther Adv Cardiovasc Dis; 2024; 18():17539447231213288. PubMed ID: 38183273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study.
    Gupta M; Wani RJ; Al Faraidy K; Bergeron J; Contreras E; Peña AAG; Mancini GBJ; Padilla F; Lopez AAP; Philip K; Wu J; Mackinnon ES
    Cardiol Ther; 2023 Dec; 12(4):703-722. PubMed ID: 37804438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies.
    Koren MJ; Jones PH; Robinson JG; Sullivan D; Cho L; Hucko T; Lopez JAG; Fleishman AN; Somaratne R; Stroes E
    Cardiol Ther; 2020 Dec; 9(2):447-465. PubMed ID: 32564340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.
    Baum SJ; Sampietro T; Datta D; Moriarty PM; Knusel B; Schneider J; Somaratne R; Kurtz C; Hohenstein B
    J Clin Lipidol; 2019; 13(6):901-909.e3. PubMed ID: 31759938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.
    Blaha V; Margoczy R; Petrov I; Postadzhiyan A; Rašlová K; Rosolová H; Bridges I; Dhalwani NN; Zachlederova M; Ray KK
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231172847. PubMed ID: 37218974
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
    Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M;
    J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.